PCSK9 Recombinant antibody

PCSK9 Uni-rAb^TM Recombinant Antibody for WB, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human

Applications

WB, ELISA

Conjugate

Unconjugated

CloneNo.

241395G1

Cat no : 84172-4-RR

Synonyms

NARC 1, LDLCQ1, HCHOLA3, FH3, EC:3.4.21.-

---

Validation Data Gallery

• 

  WB analysis of HepG2 using 84172-4-RR

  HepG2 cells were subjected to SDS PAGE followed by western blot with 84172-4-RR (PCSK9 antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

• 

  Affinity and Kinetic Characterization of 84172-4-RR

  Biolayer interferometry (BLl) kinetic assays of 84172-4-RR against Human PCSK9 were performed. The affinity constant is 0.80 nM.

---

Tested Applications

• Positive WB detected in: HepG2 cells

Recommended dilution

• Western Blot (WB): WB : 1:500-1:2000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Product Information

The immunogen of 84172-4-RR is PCSK9 Fusion Protein expressed in E. coli.

• Tested Reactivity: human
• Host / Isotype: Rabbit / IgG
• Class: Recombinant
• Type: Antibody
• Immunogen: Fusion Protein
• Full Name: proprotein convertase subtilisin/kexin type 9
• Calculated Molecular Weight: 74 kDa
• Observed Molecular Weight: 72-78 kDa, 62 kDa
• GenBank Accession Number: NM_174936.4
• Gene Symbol: PCSK9
• Gene ID (NCBI): 255738
• Conjugate: Unconjugated
• Form: Liquid
• Purification Method: Protein A purification
• Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
• Storage Conditions: Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage. 20ul sizes contain 0.1% BSA.

Background Information

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a crucial protein governing the circulating levels of low density lipoprotein-cholesterol (LDL-C), by virtue of its pivotal role in the degradation of the LDL receptor (LDLR). PCSK9 is expressed in the kidney and lung. It is synthesized as a 72 kDa immature precursor that undergoes autocatalytic cleavage in the endoplasmic reticulum to generate a 63 kDa mature protein. The cleaved N-terminal fragment remains associated with the mature protein and is necessary for its secretion, allowing it to circulate in the blood. The ability of PCSK9 to regulate a diverse group of cell-surface proteins hinted that it might also be able to influence additional membrane proteins that are important in anti-tumour immune responses. Targeting PCSK9 to treat cancer is also attractive because two neutralizing antibodies against it, evolocumab and alirocumab, have already been approved for human clinical use to lower cholesterol levels. (PMID: 30522786, PMID: 22493497)